Susan Thaul Specialist in Drug Safety and Effectiveness
I of the Food and Drug Administration Safety and Innovation Act (FDASIA, P.L.
112-144) reauthorized the Prescription Drug User Fee Act (PDUFA) through
September 30, 2017. Known as PDUFA V, this was the program’s fourth
five-year reauthorization. The Prescription Drug User Fee Act (PDUFA), in
1992, gave the Food and Drug Administration (FDA) the authority to collect
fees from the pharmaceutical industry and to use the revenue to support “the
process for the review of human drug applications.”
PDUFA fees provided 52% of the Human Drugs Program funding for FY2012,
accounting for more than 2,000 full-time equivalent employees. Therefore,
as each reauthorization deadline approaches, FDA, industry groups, and
most Members of Congress see PDUFA as must-pass legislation. Congress
originally intended PDUFA to diminish the backlog of new drug applications
at FDA and shorten the time from submission to decision. The general view is
that PDUFA has succeeded. FDA has added review staff and reduced its
review times. At each reauthorization, however, discussion returns to
certain issues in the context of PDUFA that also reflect broader FDA
concerns. The issues—and results—differ. PDUFA II expanded the user fee program’s
scope to include activities related to the investigational phases of a new drug’s development,
and to increase FDA communications with industry and consumer groups. PDUFA III
again expanded the scope of activities that user fees could support to include
both preclinical development and a three-year postapproval period. PDUFA
IV concentrated on new measures concerning postmarket drug safety.
The PDUFA V statutory language does not differ much from PDUFA IV. The
accompanying FDA-industry agreement on performance and goals and
procedures for FY2013 through FY2017 includes revised communication
procedures and timing goals during the application review process and
addresses expanded FDA efforts in regulatory science, drug development, drug safety,
and information technology.
In addition to PDUFA reauthorization, FDASIA included 10 other titles that
reauthorized medical device user fees, established generic drug and
biosimilar biological product user fees, and addressed pediatric drug
research, medical device regulation, pharmaceutical supply chain security,
antibiotic development incentives, expedited drug approval, drug shortages, and
a set of miscellaneous provisions.
Date of Report: February 22, 2013
Number of Pages: 25 Order Number: R42366 Price: $29.95
For email and phone orders, provide a Visa, MasterCard, American Express, or Discover card
number, expiration date, and name on the card. Indicate whether you want e-mail
or postal delivery. Phone orders are preferred and receive priority processing.